Dr. Mansfield Discusses Ongoing Trials With Chemoimmunotherapy in Mesothelioma


In Partnership With:

Aaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.

Aaron S. Mansfield, MD, associate professor of oncology, medical oncologist, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses ongoing trials with chemoimmunotherapy in mesothelioma.

Clinical trials evaluating chemoimmunotherapy strategies for patients with mesothelioma are likely to read out in the next few years, Mansfield says. Nonrandomized phase 2 data evaluating these regimens have yielded promising data.

However, it will be important to compare the efficacy of these combinations against standard options to determine whether chemoimmunotherapy will emerge as the standard of care for patients with mesothelioma. Currently, some of the ongoing trials are utilizing platinum-based doublet chemotherapy in the control arm, but that approach is no longer appropriate for many patients with mesothelioma, including those with non-epithelioid disease. As such, when the data read out, cross-trial comparisons may be necessary to determine whether patients should receive chemoimmunotherapy, Mansfield concludes.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS